Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group. (Q53385661)

13 May 2018

title

Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group. (English)

1 reference

13 May 2018

author name string

H C Thomas

1

1 reference

13 May 2018

A S Lok

2

1 reference

13 May 2018

V Carreño

3

1 reference

13 May 2018

G Farrell

4

1 reference

13 May 2018

H Tanno

5

1 reference

13 May 2018

V Perez

6

1 reference

13 May 2018

G M Dusheiko

7

1 reference

13 May 2018

G Cooksley

8

1 reference

13 May 2018

J C Ryff

9

1 reference

13 May 2018

publication date

1 January 1994

1 reference

13 May 2018

Journal of Viral Hepatitis

published in

1 reference

13 May 2018

volume

1

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

page(s)

139-148

1 reference

13 May 2018

Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Antibody to hepatitis-B core antigen in patients with primary hepatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Association of human hepatocellular carcinoma and cirrhosis with hepatitis B virus surface and core antigens in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Hepatitis B and primary hepatocellular carcinoma in a European population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Hepatitis B virus. The major etiology of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Decreased Interferon Response by Lymphocytes from Children with Chronic Hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Lack of in vivo activation of the interferon system in HBsAg-positive chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Relationship of HLA protein display to activation of 2-5A synthetase in HBe antigen or anti-HBe positive chronic HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Randomised controlled trial of adenine arabinoside 5'-monophosphate (ARA-AMP) in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Acyclovir inhibits hepatitis B virus replication in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Acyclovir in hepatitis B antigen-positive chronic liver disease: inhibition of viral replication and transient renal impairment with iv bolus administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Randomised controlled trial of interferon alfa 2A (rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Defective response to interferons in cells transfected with the hepatitis B virus genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.1994.TB00113.X

10.1111/J.1365-2893.1994.TB00113.X

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

release_iqm2ug4cr5c3djhjuteafb4pli

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iqm2ug4cr5c3djhjuteafb4pli

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

13 May 2018